Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Mastocytosis 4Pruritus 2Piebaldism 2Mastocytosis, Systemic 2Blushing 2

Interventions

avapritinib 5midostaurin 4masitinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Phlebotomy 1Interviews as Topic 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Dasatinib 1Cladribine 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × masitinib × Myeloid × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡